analysts and calls -- Goldman Sachs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- Goldman Sachs

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: Icebrg who started this subject	9/27/2002 12:32:44 PM
From: Icebrg	Read Replies (1) of 4

RESEARCH ALERT-Lehman rates Barr stock 'overweight' Friday September 27, 12:00 pm ET NEW YORK, Sept 27 (Reuters) - Lehman Brothers on Friday rated shares of Barr Laboratories Inc. (NYSE:BRL - News) as "overweight," saying Barr has one of the best stables of generic drugs soon to hit the market. Analyst Richard Silver placed a 12-month price target of $80 on Barr's stock. Shares of Barr closed at $62.99 on the New York Stock Exchange on Thursday. Barr gained notoriety last year for winning a court battle that permitted it to market a generic form of the blockbuster antidepressant Prozac. Although the company's six months U.S. generic exclusivity has expired, Barr has taken advantage of other patent expirations, particularly by marketing copycat versions of oral contraceptives. "Barr has one of the industry's richest, most attractive and fastest growing generic pipelines," Silver wrote in a research note. Silver added that Barr is also developing its own branded drugs, which could drive long-term revenue growth.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext